HRMY SEC Filing News — Harmony Biosciences Holdings, Inc.

Latest SEC filings for Harmony Biosciences Holdings, Inc. (HRMY) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-13.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical tr…
Sector: Healthcare Industry: Biotechnology Market Cap: $2.2B
20
Total Filings
0
Bullish Classifications
3
Bearish Classifications
3
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for HRMY currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
HRMY Filing Activity Snapshot 2026-05-18 — 2026-10-13
Insider Transactions (Form 4)
0 buys vs 2 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$26.56M
VALOR IV PHARMA HOLDINGS LLC · 2026-08-07
700,883 shares · Form 144
Form 144 Notices
13
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 3 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 3 filings in this group are Form 4s for Harmony Biosciences Holdings, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 3 insider filings shown, the breakdown is 2 open-market sale and 1 compensation award. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×2
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×1
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market sale Insider Selling 2026-09-18

HRMY insider Budur Kumar (CHIEF MEDICAL OFFICER) sold 38,452 shares (~$1.66M)

Budur Kumar, listed as CHIEF MEDICAL OFFICER at Harmony Biosciences Holdings, Inc., reported an open-market sale of 38,452 HRMY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 900 $30.69 $27.6K
M Option exercise 900 $30.27 $27.2K
S Open-market sale 1,800 $43.01 $77.4K
M Option exercise 400 $30.69 $12.3K
M Option exercise 400 $30.27 $12.1K
S Open-market sale 800 $43.00 $34.4K
M Option exercise 10,406 $30.69 $319.4K
M Option exercise 25,446 $30.27 $770.3K
S Open-market sale 35,852 $43.05 $1.54M
M Option exercise derivative · Stock Option 900 — —
M Option exercise derivative · Stock Option 900 — —
M Option exercise derivative · Stock Option 400 — —
M Option exercise derivative · Stock Option 400 — —
M Option exercise derivative · Stock Option 10,406 — —
M Option exercise derivative · Stock Option 25,446 — —
Filing: Form 4 (Insider Transaction) Insider: Budur Kumar (CHIEF MEDICAL OFFICER) Shares: 38,452 Est. Value: $1.66M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-09

HRMY insider Budur Kumar (CHIEF MEDICAL OFFICER) sold 33,954 shares (~$1.45M)

Budur Kumar, listed as CHIEF MEDICAL OFFICER at Harmony Biosciences Holdings, Inc., reported an open-market sale of 33,954 HRMY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,500 $41.98 $230.9K
S Open-market sale 4,500 $42.25 $190.1K
S Open-market sale 1,000 $42.79 $42.8K
M Option exercise 12,200 $30.69 $374.4K
M Option exercise 10,754 $30.27 $325.5K
S Open-market sale 22,954 $43.10 $989.3K
M Option exercise derivative · Stock Option 12,200 — —
M Option exercise derivative · Stock Option 10,754 — —
Filing: Form 4 (Insider Transaction) Insider: Budur Kumar (CHIEF MEDICAL OFFICER) Shares: 33,954 Est. Value: $1.45M
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-18

HRMY insider Form 4 filed for equity award, exercise, or tax withholding

Germano Geno J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option 21,231 — —
Filing: Form 4 (Insider Transaction) Insider: Germano Geno J (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 13 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Harmony Biosciences Holdings, Inc. has 13 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-18

HRMY Form 144 filed for proposed insider sale by KUMAR BUDUR (35,852 shares) ~$1.53M

KUMAR BUDUR filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR BUDUR Shares: 35,852 Est. Value: $1.53M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-17

HRMY Form 144 filed for proposed insider sale by KUMAR BUDUR (800 shares) ~$33.8K

KUMAR BUDUR filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR BUDUR Shares: 800 Est. Value: $33.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-16

HRMY Form 144 filed for proposed insider sale by KUMAR BUDUR (1,800 shares) ~$75.9K

KUMAR BUDUR filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR BUDUR Shares: 1,800 Est. Value: $75.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-08

HRMY Form 144 filed for proposed insider sale by KUMAR BUDUR (28,454 shares) ~$1.20M

KUMAR BUDUR filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR BUDUR Shares: 28,454 Est. Value: $1.20M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-04

HRMY Form 144 filed for proposed insider sale by KUMAR BUDUR (5,500 shares) ~$230.2K

KUMAR BUDUR filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KUMAR BUDUR Shares: 5,500 Est. Value: $230.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-07

HRMY Form 144 filed for proposed insider sale by VALOR IV PHARMA HOLDINGS LLC (700,883 shares) ~$26.56M

VALOR IV PHARMA HOLDINGS LLC filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: VALOR IV PHARMA HOLDINGS LLC Shares: 700,883 Est. Value: $26.56M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-02

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (25,000 shares) ~$924.0K

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 25,000 Est. Value: $924.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-30

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (50,000 shares) ~$1.80M

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 50,000 Est. Value: $1.80M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-26

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (45,594 shares) ~$1.61M

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 45,594 Est. Value: $1.61M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-24

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (4,406 shares) ~$154.3K

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 4,406 Est. Value: $154.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-09

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (27,960 shares) ~$943.3K

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 27,960 Est. Value: $943.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-05

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (2,101 shares) ~$69.5K

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 2,101 Est. Value: $69.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-04

HRMY Form 144 filed for proposed insider sale by SANDIP KAPADIA (7,064 shares) ~$233.2K

SANDIP KAPADIA filed a Form 144 with the SEC indicating intent to sell HRMY (Harmony Biosciences Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SANDIP KAPADIA Shares: 7,064 Est. Value: $233.2K
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Harmony Biosciences Holdings, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-13

HRMY filed 8-K — material company event

Harmony Biosciences Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-04

HRMY filed 8-K — material company event

Harmony Biosciences Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-16

HRMY filed 8-K — material company event

Harmony Biosciences Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Harmony Biosciences Holdings, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

HRMY filed Quarterly Report (10-Q)

Harmony Biosciences Holdings, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Harmony Biosciences Holdings, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on HRMY. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — HRMY SEC Filings

More Tools for HRMY

HRMY Full Stock Analysis HRMY Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper HRMY analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the HRMY stock analysis page.

HRMY Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer